A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users

Summary

Dimebon will not exhibit abuse potential when compared to placebo or a positive control (alprazolam).

Timeline

Start

2009-10

Primary completion

2010-02

Completion

2010-02

Outcome

Missed primary endpoint

registry analysis (superiority or other test); Placebo vs Dimebon 20 mg; p = 0.8428; Mean Difference (Final Values) -0.5792 (95% CI -6.3385 to 5.1800); Mixed Models Analysis NCT00975481 ↗

registry analysis (superiority or other test); Placebo vs Dimebon 20 mg; p = 0.6029; Mean Difference (Final Values) -1.6121 (95% CI -7.7209 to 4.4967); Mixed Models Analysis NCT00975481 ↗

registry analysis (superiority or other test); Placebo vs Dimebon 20 mg; p = 0.2239; Mean Difference (Final Values) -6.3979 (95% CI -16.7479 to 3.9521); Mixed Models Analysis NCT00975481 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Alprazolam	Small molecule	1 mg	Oral
Comparator	Alprazolam	Small molecule	3 mg	Oral
Subject	Latrepirdine	Small molecule	20 mg	Oral
Subject	Latrepirdine	Small molecule	40 mg	Oral
Subject	Latrepirdine	Small molecule	60 mg	Oral

Indications